Drug intelligence / Profile preview

Anti-CD19 CAR-T cells (University of Utah)

Development stage: Unknown
Lead developer: University of Utah
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

Anti-CD19 CAR-T cells (University of Utah) is an autologous chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of relapsed or refractory CD19-positive B-cell malignancies, including non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The therapy utilizes a second-generation CAR construct consisting of a murine anti-human CD19 single-chain variable fragment (scFv) derived from the FMC63 clone, linked to a 4-1BB (CD137) costimulatory domain and a CD3-zeta signaling domain. A notable feature of this program is the use of the Miltenyi Biotec CliniMACS Prodigy platform for automated, closed-system manufacturing (CellReGen process), which incorporates a transmembrane domain derived from TNFRSF19. This approach is designed to improve the consistency and scalability of CAR-T production within an academic clinical setting.

Other names: Anti-CD19 CAR-T cellsAnti-CD-19 CAR-T cellsAnti-CD 19 CAR-T cellsUU-CD19-CAR-TUU-CD-19-CAR-TUU-CD 19-CAR-TCD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cells

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on Anti-CD19 CAR-T cells (University of Utah).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-CD19 CAR-T cells (University of Utah).

Explore the full profile